TScan Therapeutics, Inc. reports clinical and corporate developments for its T cell receptor-engineered T cell therapy pipeline. The company’s cancer programs include TSC-101 in the ALLOHA heme trial for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, and CD45-targeted candidates TSC-102-A01 and TSC-102-A03 with cleared IND applications.
Recurring TCRX updates cover clinical data presentations, trial enrollment and manufacturing-process updates, FDA interactions, financial results, healthcare conference participation, and portfolio priorities. The company also describes early work in in vivo engineering for solid tumors and target discovery in T cell-mediated autoimmune disorders.
TScan Therapeutics (Nasdaq: TCRX) completed enrollment in Cohort C of its Phase 1 ALLOHA™ study, treating patients with a new commercial-ready manufacturing process and enrolling over ten patients. The company also received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 (HLA A*01:01 and A*03:01).
TScan plans to share Cohort C safety and early chimerism data in Q2 2026, launch a pivotal TSC-101 trial in Q2 2026, and initiate Phase 1 studies for both TSC-102 candidates in the second half of 2026.
TScan Therapeutics (Nasdaq: TCRX) will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 11:50 a.m. ET in Boston.
The hybrid presentation includes an analyst Q&A and a live webcast via the company’s Events and Presentations page, with an archived replay available for 90 days.
TScan Therapeutics (NASDAQ: TCRX) reported updated ALLOHA™ Phase 1 data for TSC-101 in heme malignancy patients undergoing allogeneic HCT presented at ASH on Dec 6, 2025. As of a Sept 19, 2025 cut, treatment-arm outcomes showed improved relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) versus control.
All 3 TSC-101 patients reaching two-year follow-up remained relapse-free versus 1 of 4 in control. No dose-limiting toxicities were observed. FDA agreed to a pivotal study design; pivotal start targeted Q2 2026. Manufacturing time reduced from 17 to 12 days.
TScan Therapeutics (Nasdaq: TCRX) will host a virtual key opinion leader event on December 8, 2025 at 8:00 a.m. ET to discuss updated data from the ALLOHA™ Phase 1 trial and the market opportunity for its heme program.
The event will review a poster presented at the 67th ASH Annual Meeting, including two-year relapse data from initial patients in the ALLOHA trial of TSC-101 in heme malignancy patients undergoing allogeneic HCT, the company’s newly implemented commercial-ready manufacturing process, and plans for a pivotal trial slated to start in Q2 2026. A replay will be available on the company’s Events and Presentations page.
TScan (Nasdaq: TCRX) reported Q3 2025 results and a corporate update on Nov 12, 2025. Key developments include a negotiated pivotal trial design with the FDA for TSC-101, an implemented commercial-ready manufacturing process that shortens production by five days, and a strategic shift to prioritize the heme program while pausing further enrollment in the PLEXI-T solid tumor trial to focus on in vivo engineering.
Financials: Q3 revenue was $2.5M vs $1.0M year-ago; R&D expense was $31.7M; net loss was $35.7M; cash and marketable securities were $184.5M, projected to fund operations into H2 2027. Updated ALLOHA data will be presented at ASH on Dec 6, 2025.
TScan Therapeutics (Nasdaq: TCRX) will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 10:00 a.m. ET at the InterContinental Boston.
A live webcast will be available in the company’s Events and Presentations section at ir.tscan.com, and an archived replay will remain on the site for 90 days after the event.
TScan (Nasdaq: TCRX) reached alignment with the FDA on a pivotal registrational trial design for TSC-101 in AML and MDS following an End-of-Phase 1 meeting. The pivotal trial will mirror the Phase 1 ALLOHA study and use a biologically assigned internal control arm; the company expects to start the pivotal trial in Q2 2026. TScan shortened its manufacturing process from 17 to 12 days to reduce ex vivo T cell expansion and transferred the process to a CDMO.
The company dosed the first two solid tumor patients with multiplex TCR-T, paused further solid-tumor enrollment to prioritize heme development, enacted a workforce reduction of ~30% (66 employees), expects ~$45.0 million annual cost savings in 2026–2027, will take a one-time charge up to $2.3 million in Q4 2025, and extended cash runway into H2 2027. Key near-term milestones: ASH presentation on Dec 6, 2025, INDs for expanded HLA coverage in Q4 2025, and initial PLEXI-T data in Q1 2026.
TScan Therapeutics (Nasdaq: TCRX) announced two abstract acceptances for presentation at the American College of Rheumatology (ACR) Convergence 2025 in Chicago. The company will deliver an oral presentation on CD8+ T cell targets in Ankylosing Spondylitis and Birdshot Uveitis, and a poster presentation on HLA Class II-restricted autoantigens in Scleroderma and Ulcerative Colitis.
While primarily focused on oncology, TScan's proprietary TargetScan technology has identified several shared T-cell targets in Ankylosing Spondylitis, representing a potential breakthrough in an area where therapeutic targets have remained elusive. The presentations will showcase the platform's capabilities in identifying novel targets for autoimmune disorders.
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in two upcoming investor conferences.
The company will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 5:35 p.m. ET, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9:00 a.m. ET. Both presentations will be available via webcast on the company's investor relations website for 90 days following the events.
TScan Therapeutics (Nasdaq: TCRX) reported Q2 2025 financial results and provided updates on its TCR-T therapy programs. The company reported revenue of $3.1 million and a net loss of $37.0 million. Key developments include plans to dose first solid tumor patients with multiplex TCR-T in Q3 2025 and present two-year relapse data from the ALLOHA™ Phase 1 heme trial by year-end.
The company's cash position stands at $218.0 million, expected to fund operations into Q1 2027. TScan plans to initiate a registrational trial for TSC-101 in H2 2025 and file an IND for TSC-102-A0301. Initial safety and response data from the PLEXI-T trial is expected in Q1 2026.